Atopic Dermatitis

Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.

Roflumilast cream .05% for mild to moderate atopic dermatitis in children also met secondary endpoints.

The Small Business Innovation Research grant enables ResVita Bio to develop RVB-101 for treatment of severe atopic dermatitis.

Skin clearance and itch relief were maintained through 1 year of treatment with monthly maintenance.

According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.

World Atopic Eczema Day initiative from Almirall highlights experiences and facts about atopic dermatitis.

Nektar Therapeutics announced the promising and statistically significant results, which included meeting endpoints of BSA, DLQI and POEM in patients with atopic dermatitis.

The submission follows the announcement of recent long-term data of the drug in patients ages 6 years and older.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.

As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.

Experts discuss how new data are evolving standards of care for atopic dermatitis (AD) in terms of safety and redefining response to therapy.

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.

Researchers found an association between ADHD and three inflammatory conditions—atopic dermatitis, otitis media, and herpes simplex infection.

The post hoc analysis published in JAMA Dermatology studied the safety and efficacy of tralokinumab in adults aged 65 and older.

Among children and adolescents with atopic dermatitis, higher severity led to more school absences.

The OX40 monoclonal antibody possesses an extended half-life. In a previous study, this half-life exceeded that of the average conventional IgG.

Acne was mild to moderate in severity and successfully managed with topical or oral treatments.

Ruth Ann Vleugels, MD, MPD, MBA, provides important considerations for clinicians when reflecting upon the safety of oral Janus Kinase (JAK) inhibitors and traditional systemic immunosuppressants.

Trinity Flint shares her experience using upadacitinib to treat atopic dermatitis and the impact it has had on her quality of life.

Diego Ruiz Dasilva, MD, FAAD, shares treatment approaches to atopic dermatitis, focusing on medications such as dupilumab and upadacitinib.

Patients given LNK01001 showed significant improvement in EASI scores over placebo.

Christopher Bunick, MD, PhD, discusses the major study conclusions about the safety of upadacitinib as a treatment for atopic dermatitis.

Christopher Bunick, MD, PhD, presents the results of the long-term four-year safety study of upadacitinib as treatment for atopic dermatitis (AD).

Leading atopic dermatitis experts delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.

Trinity Flint reviews the topical treatments she was prescribed in the early stages of atopic dermatitis and her response to treatment.

A dermatologist and a patient discuss the importance of having a multidisciplinary team approach to treating atopic dermatitis.

Researchers found that the Comfiknit Atopic Eczema T-shirt reduced Eczema Area and Severity Index scores.

Peter Lio, MD, discusses pearls and takeaways from the atopic dermatitis panel he participated in at the 2023 Society of Pediatric Dermatology meeting.